3 citations
,
February 2019 in “Der Urologe” This review discusses the risk of central nervous side effects, such as dementia and depression, from drugs used to treat lower urinary symptoms related to benign prostatic hyperplasia, and highlights inconsistent evidence across different medications.
35 citations
,
May 2020 in “Frontiers in Pharmacology” This review provides a comprehensive overview of the mechanisms, efficacy, and adverse reactions of drugs commonly used for treating benign prostatic hyperplasia but reports no new clinical results.
5 citations
,
December 2024 in “Archivio Italiano di Urologia e Andrologia” This review discusses medical therapies for benign prostatic hyperplasia, highlighting the importance of personalizing treatments to individual patient needs and preferences.
20 citations
,
August 2019 in “Expert Opinion on Drug Safety” This review examines the cognitive effects of medications for lower urinary tract symptoms and indicates that muscarinic antagonists, particularly oral oxybutynin, pose the highest risk for cognitive impairment.
January 2022 in “Galenika Medical Journal” This article reviews the management of lower urinary tract symptoms, highlighting drug therapy advancements that have reduced the frequency of surgical interventions.